Managing Agitation in Patients with Hepatic Impairment

Primary Recommendations

The American College of Oncology recommends olanzapine at reduced doses (starting 2.5 mg orally or subcutaneously) as the preferred alternative antipsychotic for managing agitation in patients with hepatic impairment, with lorazepam (0.5-1 mg) as an alternative for severe agitation or when combined therapy is needed 1
The National Comprehensive Cancer Network (NCCN) guidelines recommend starting with 2.5 mg orally or subcutaneously for initial management of agitation, with the option to repeat dosing if needed, while maintaining lower total daily doses in hepatic dysfunction 1
Olanzapine is available as an orally disintegrating tablet (ODT) for patients who cannot swallow, and for severe agitation requiring a parenteral route, olanzapine 2.5 mg subcutaneous is preferred over higher doses 1
The NCCN guidelines also recommend watching for orthostatic hypotension and drowsiness, which are more pronounced in hepatically impaired patients, and avoiding combining olanzapine with benzodiazepines due to the risk of oversedation and respiratory depression 1, 3

The NCCN guidelines recommend risperidone as another atypical antipsychotic suitable for hepatic impairment, starting with 0.5 mg orally for acute agitation, with dose reduction mandatory in severe hepatic impairment 1, 4
Quetiapine offers sedating properties useful for agitation, starting with 25 mg orally (immediate release), with dose reduction required in hepatic impairment, and is less likely to cause extrapyramidal symptoms than other atypicals 1
Lorazepam is appropriate for severe agitation or as a crisis medication, with 0.5-1 mg subcutaneous or IV for patients with hepatic impairment, and may be combined with atypical antipsychotics for refractory agitation, but avoid combining with olanzapine 1, 3

The NCCN guidelines recommend avoiding haloperidol due to the requirement for dose reduction in hepatic failure and the higher QTc prolongation risk 4, 5
Thioridazine is absolutely contraindicated due to its greatest QTc prolongation effect (25-30 ms) 2

For cooperative patients with mild-moderate agitation, the first choice is olanzapine 2.5 mg orally, the second choice is risperidone 0.5 mg orally, and the third choice is quetiapine 25 mg orally 1
For severe agitation or non-cooperative patients, the first choice is olanzapine 2.5 mg subcutaneous, and the alternative is lorazepam 0.5-1 mg subcutaneous/IV (monitor for hepatic encephalopathy) 1

All medication doses must be reduced in hepatic impairment, with the NCCN guidelines explicitly stating to "decrease doses of medications dependent upon hepatic or renal failure" 4, 5
Monitor closely for oversedation, as hepatically impaired patients metabolize medications more slowly, and obtain baseline ECG if cardiac risk factors are present, as multiple antipsychotics can prolong QTc 1, 3, 2